A myelodysplastic syndrome characterized by dysplasia seen in at least 10% of the early cells of 1 cell type (either red blood cells, white blood cells, or megakaryocytes) in the bone marrow.
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation for myelodysplastic syndrome with single lineage dysplasia is limited due to its rarity and the lack of systematic clinical studies. Conditions like MDS-SLD affect a small number of individuals, which makes comprehensive research difficult. Additionally, the phenotypic features have not been thoroughly characterized, contributing to the gaps in available information.
To navigate your care for myelodysplastic syndrome with single lineage dysplasia, consider consulting a hematologist with expertise in myelodysplastic syndromes. Engaging with clinical trials may provide access to new therapies, and you can find active studies at ClinicalTrials.gov. Additionally, genetic counseling can be beneficial, even without known genetic causes, to discuss family implications and future planning. For more resources, you can visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
There are several orphan drugs associated with MDS-SLD, including FDA-approved treatments like imetelstat and luspatercept-aamt. Additionally, various drugs are designated for development, such as Epoetin alfa and thalidomide. There are currently 182 active clinical trials for myelodysplastic syndrome, which can be explored further at ClinicalTrials.gov. This research landscape offers hope for future treatment options and insights into the condition.
Actionable guidance for navigating care for myelodysplastic syndrome with single lineage dysplasia
To navigate your care for myelodysplastic syndrome with single lineage dysplasia, consider consulting a hematologist with expertise in myelodysplastic syndromes. Engaging with clinical trials may provide access to new therapies, and you can find active studies at ClinicalTrials.gov. Additionally, genetic counseling can be beneficial, even without known genetic causes, to discuss family implications and future planning. For more resources, you can visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for myelodysplastic syndrome with single lineage dysplasia is limited due to its rarity and the lack of systematic clinical studies. Conditions like MDS-SLD affect a small number of individuals, which makes comprehensive research difficult. Additionally, the phenotypic features have not been thoroughly characterized, contributing to the gaps in available information.
To navigate your care for myelodysplastic syndrome with single lineage dysplasia, consider consulting a hematologist with expertise in myelodysplastic syndromes. Engaging with clinical trials may provide access to new therapies, and you can find active studies at ClinicalTrials.gov. Additionally, genetic counseling can be beneficial, even without known genetic causes, to discuss family implications and future planning. For more resources, you can visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
There are several orphan drugs associated with MDS-SLD, including FDA-approved treatments like imetelstat and luspatercept-aamt. Additionally, various drugs are designated for development, such as Epoetin alfa and thalidomide. There are currently 182 active clinical trials for myelodysplastic syndrome, which can be explored further at ClinicalTrials.gov. This research landscape offers hope for future treatment options and insights into the condition.
Actionable guidance for navigating care for myelodysplastic syndrome with single lineage dysplasia
To navigate your care for myelodysplastic syndrome with single lineage dysplasia, consider consulting a hematologist with expertise in myelodysplastic syndromes. Engaging with clinical trials may provide access to new therapies, and you can find active studies at ClinicalTrials.gov. Additionally, genetic counseling can be beneficial, even without known genetic causes, to discuss family implications and future planning. For more resources, you can visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation for myelodysplastic syndrome with single lineage dysplasia is limited due to its rarity and the lack of systematic clinical studies. Conditions like MDS-SLD affect a small number of individuals, which makes comprehensive research difficult. Additionally, the phenotypic features have not been thoroughly characterized, contributing to the gaps in available information.
To navigate your care for myelodysplastic syndrome with single lineage dysplasia, consider consulting a hematologist with expertise in myelodysplastic syndromes. Engaging with clinical trials may provide access to new therapies, and you can find active studies at ClinicalTrials.gov. Additionally, genetic counseling can be beneficial, even without known genetic causes, to discuss family implications and future planning. For more resources, you can visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
There are several orphan drugs associated with MDS-SLD, including FDA-approved treatments like imetelstat and luspatercept-aamt. Additionally, various drugs are designated for development, such as Epoetin alfa and thalidomide. There are currently 182 active clinical trials for myelodysplastic syndrome, which can be explored further at ClinicalTrials.gov. This research landscape offers hope for future treatment options and insights into the condition.
Actionable guidance for navigating care for myelodysplastic syndrome with single lineage dysplasia
To navigate your care for myelodysplastic syndrome with single lineage dysplasia, consider consulting a hematologist with expertise in myelodysplastic syndromes. Engaging with clinical trials may provide access to new therapies, and you can find active studies at ClinicalTrials.gov. Additionally, genetic counseling can be beneficial, even without known genetic causes, to discuss family implications and future planning. For more resources, you can visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.